リリースコンテナ第3倉庫

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, announced today that it has again been named one of The Boston Globe’s Top Places to Work.

The Boston Globe’s 2013 Top Places to Work survey, conducted by WorkplaceDynamics, measured responses of employees from numerous organizations in Massachusetts to statements regarding six key factors related to employee happiness, including company direction, execution, employee connection, work load and responsibility, management, and pay and benefits. More than 76,000 individuals responded to the survey. Among survey respondents, greatest importance was placed on aspects related to employee appreciation and feeling that their work is meaningful. WorkplaceDynamics also found that, of all the cities surveyed, employees in the Boston area were most enthusiastic about their companies, making Boston the top of the Top Places to Work.

Daniel Junius, President and CEO, commented, “ImmunoGen is focused on developing and advancing meaningful new treatments for cancer. To succeed in this mission, it is essential that we hire and retain top quality people. We are extremely pleased that our supportive culture and other key aspects of working at ImmunoGen are reflected in the survey responses and that our company has again been recognized as one of The Boston Globe’s Top Places to Work.”

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company’s ADC technology uses a tumor-targeting engineered antibody to deliver one of ImmunoGen's highly potent cancer-cell killing agents specifically to tumor cells. The most advanced compound with ImmunoGen’s ADC technology is Roche’s Kadcyla^®, which is marketed in the US by Genentech and is also gaining approvals internationally. Additional compounds are in clinical testing by ImmunoGen and through the Company’s partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. More information about ImmunoGen can be found at www.immunogen.com.

Kadcyla^® is a registered trademarks of Genentech, Inc., a member of the Roche Group.

At Sunday’s opening day of the Dubai Air Show, GE Aviation received $26 billion (USD list price) in jet engine orders and services agreements for wide-body Boeing aircraft from three leading airlines in the Middle East.

“Our business succeeds by establishing long term strategic partnerships to ensure we can offer our customers the best. This deal allows us to do that.”

Collectively, Emirates, Qatar Airways, and Etihad Airways ordered 450 of the new GE9X engine now under development for the new Boeing 777X. GE also received orders for GEnx engines for the Boeing 787 and GE90 engines for the Boeing 777. The airline engine orders:

EMIRATES:

With the commitment by Emirates airlines for 150 Boeing 777X twin-engine aircraft, GE Aviation has secured its largest ever commercial jet engine award from an airline.

Among the world’s fastest growing airlines, Emirates has committed to acquiring 300 GE9X engines for its new 777X fleet. The agreement for the GE9X engines is worth more than $11 billion (USD) list price.

Emirates is already the world’s largest operator of the highly successful GE90-powered Boeing 777-300ERs, with a fleet of 135 aircraft. Emirates also operates the largest fleet of A380s powered by the GP7200 engine produced by the Engine Alliance, a joint company of GE Aviation and Pratt & Whitney.

But the relationship between GE Aviation and Emirates over the past decade has extended beyond the delivery and support of jet engines. GE has been integral to the construction of Emirates’ expanding engine overhaul capability both in the Middle East and Asia.

“We are pleased to expand upon our strong relationship with GE Aviation for this 777X aircraft order of great strategic importance to our airline,” said H.H. Sheikh Ahmed bin Saeed Al-Maktoum, chairman and chief executive of Emirates Airline & Group.

“The confidence placed by Emirates in GE Aviation is almost overwhelming,” said David Joyce, president and CEO of GE Aviation. “Emirates is critical in enabling GE to demonstrate and improve upon its high-thrust engine technologies. The success in service of the GE90-powered 777-300ER paved the way for the industry’s enthusiasm for the GE9X-powered 777X. And Emirates has been there for the whole remarkable journey.”

Selected earlier this year to power the Boeing 777X, the GE9X will feature several technology breakthroughs, including aviation’s largest-diameter front fan and highest pressure-ratio compressor, and unique ceramic matrix composite, hot-section components.

ETIHAD:

Etihad Airways selected GE engines to power its order for 56 Boeing wide-body aircraft. The order includes a commitment for 25 GE9X-powered Boeing 777X, 30 GEnx-1B-powered Boeing 787-10, and one GE90-115B-powered Boeing 777-200LR aircraft. The list price for these engines is valued at more than $3 billion (USD).

Etihad Airways has also agreed to 15-year OnPoint^SM solution agreements to cover all the engines in this order. The OnPoint solution agreements are valued at $8 billion over the life of the contract.

“This order demonstrates Etihad Airways’ commitment to operating one of the most technically advanced and fuel efficient fleets in the industry, now and in the future,” said James Hogan, Etihad Airways’ president and chief executive. “Our business succeeds by establishing long term strategic partnerships to ensure we can offer our customers the best. This deal allows us to do that.”

“We are honored Etihad has selected GE to play a significant role in the airline’s expansion efforts,” said David Joyce, president and chief executive officer of GE Aviation. “GE’s wide-body engine strategy builds on the solid foundation that we began with our GE90 engines, was advanced with new technologies in the outstanding GEnx and will evolve further with the new GE9X engine, which will be the largest fan diameter and most fuel efficient engine GE has ever designed and manufactured.”

QATAR:

Qatar Airways ordered 50 GE9X-powered Boeing 777X aircraft. List price for these engines is valued at $3.8 billion (USD).

“Qatar Airways continues its rapid growth and GE is proud to play a significant role in the expansion with this order for GE9X-powered Boeing 777X aircraft,” said David Joyce, president and chief executive officer of GE Aviation. “The new GE9X engine will be the largest and most fuel efficient engine GE has ever designed and manufactured and the rising number of orders for the engine-aircraft combination serve as a testament to the confidence our customers have in the product.”

The GE9X engine for Boeing's 777X aircraft will be in the 100,000-pound thrust class with a 10 percent improvement in fuel burn over today's GE90-115B. Key features include: the industry’s largest front fan, composite fan case and fourth-generation composite fan blades, highest pressure ratio compressor for any large GE engine, third-generation TAPS (twin annular pre-swirl) combustor for greater efficiency and low emissions, and ceramic matrix composite (CMC) material in the combustor and turbine.

Qatar Airways has seen rapid growth in just 16 years of operations, currently flying a modern fleet of 128 aircraft to 133 key business and leisure destinations across Europe, Middle East, Africa, Asia Pacific and The Americas. Qatar Airways recently joined the oneworld Alliance, becoming the only major Gulf carrier to join a global airline alliance, enabling its customers to benefit from almost a thousand airports in more than 150 countries, with 14,000 daily departures.

Qatar Airways currently has orders worth over US$50 billion for more than 250 aircraft, including Boeing 787s, 777s, Airbus A380 and A320 family of aircraft. For more information, visit www.qatarairways.com.

GE Aviation, an operating unit of GE (NYSE: GE), is a world-leading provider of jet, turboprop and turboshaft engines, components and integrated systems for commercial, military, business and general aviation aircraft. GE Aviation has a global service network to support these offerings. For more information, visit us at www.ge.com/aviation. Follow GE Aviation on Twitter at http://twitter.com/GEAviation and YouTube at http://www.youtube.com/user/GEAviation.

)--Third graph, third sentence of release dated November 16, 2013 should read: The company’s stock was trading at a split-adjusted $60.56 upon Reynolds’ departure (sted The company’s stock was trading at $60.56 upon Reynolds’ departure).

“Parkinson’s disease ravaged my father’s brain for 25 years. I’ve been consumed with the disease for 35 years now and we’re laser beam focused to help as soon as possible.”

The corrected release reads:

INVIVO THERAPEUTICS FOUNDERS TAKE ON PARKINSON’S DISEASE WITH PIXARBIO CORPORATION

PixarBio Corporation announces its formation to research and develop novel biomaterials for long term-personalized drug delivery systems for Parkinson’s Disease.

PixarBio’s founding team includes InVivo Therapeutics co-founders Frank Reynolds, and Robert S. Langer ScD, David H. Koch Institute Professor at the Massachusetts Institute of Technology, as well as polymer industry veteran Randy Holmes-Farley PhD and Katrin Holzhaus, an entrepreneur with a proven track record of success.

Founding Team Highlights:

Frank Reynolds, CEO/CFO: serial entrepreneur winning global awards as both scientist and business leader, co-inventor on 38 patent applications. Reynolds co-founded InVivo Therapeutics (NVIV) growing its value from $0.01 at founding to a split-adjusted high of $85.37. The company’s stock was trading at a split-adjusted $60.56 upon Reynolds’ departure.

Robert S. Langer, Co-Founder: David H. Koch Institute Professor at the Massachusetts Institute of Technology. Dr. Langer holds more than 800 life science patents - more than any other person in history. His technologies have been licensed by over 250 companies around the world.

Randy Holmes-Farley, Chief Technology Officer: Holmes-Farley earned his PhD in George Whiteside Lab at Harvard, and is now a leading researcher in the field of therapeutic polymers and biomaterials and co-inventor of three approved polymer pharmaceuticals, 72 US patents, and 35 journal publications. He previously held the position of Vice President, Drug and Biomaterial R&D at Genzyme and Director of Chemical Research at GelTex Pharmaceuticals, among others.

Katrin Holzhaus, Chief Operating Officer: a serial entrepreneur who’s teaming with Frank Reynolds for a 3^rd time over the last 13 years, has an established track record of success. Holzhaus will use her established methods and procedures to keep PixarBio operations optimized.

Said PixarBio’s CEO Reynolds: “We are excited about adding Randy Holmes-Farley to our experienced team of founders. His background and vision perfectly align with PixarBio’s mission. I’m also thrilled to announce an agreement for our first R&D facility in Medford, MA close to our innovation and academic roots at Harvard and MIT. More on the R&D facility will be announced in the coming weeks. Lastly,” Reynolds said “Parkinson’s disease ravaged my father’s brain for 25 years. I’ve been consumed with the disease for 35 years now and we’re laser beam focused to help as soon as possible.”

Parkinson’s Disease (PD)

• Effecting 1% of all people over 50 years old
• Over 1 million Americans suffer from PD
• Over 10 million worldwide suffer from PD
• It is estimated that PD costs in the U.S. exceed $25 billion annually
• In 1900 there were 3.5 million people over age 65; in 2010, there were over 40 million.

About PixarBio

PixarBio Corporation is dedicated to developing new therapeutic options for Parkinson’s disease. Co-founded by Robert S. Langer from MIT’s Langer Lab and Frank Reynolds, the company is developing novel smart materials to achieve sustained release of dopamine, or dopamine agonists. Research is focused on a platform for chronic neurological applications. The company is headquartered in Salem, NH. For more information, please visit www.pixarbio.com.

Today’s aircraft orders totaling $162.6 Billion by state-owned foreign airlines Emirates, Etihad Airways, Qatar Airways, and Flydubai, illustrate the staggering scale of the economic threat to the U.S. airline industry and its employees if the U.S. government continues policies that hand foreign competitors an economic advantage over U.S. airlines in the global marketplace.

“The secretary general of the Arab Air Carriers Organization had it half-right in an April 2011 speech to the International Aviation Club in which he compared the U.S. airline industry to dinosaurs that will soon die due to their inability to adapt to their environment”

So far, the total order during the first day of the Dubai Airshow includes the purchase of 113 widebody aircraft from Airbus and 255 from Boeing. “The question of the day is: How many of these widebody aircraft orders will be financed by a U.S. or European taxpayer-backed export credit agency, subsidizing the aircraft orders at rates not available to U.S. airlines,” said Capt. Lee Moak, President of the Air Line Pilots Association, Int’l (ALPA).

ALPA calls for the U.S. government to provide U.S. airlines and their workers with a fair opportunity to compete internationally by ending its policies that advantage state-owned foreign airlines while harming U.S. airlines. In Leveling the Playing Field for U.S. Airlines and Their Employees, ALPA lays out urgently needed U.S. government action, including measures to:

• Reform the high tax burden on U.S. airlines while their foreign competitors often operate in a tax-free business environment at home;
• Halt its plan to operate U.S. Customs preclearance facilities in Abu Dhabi and possibly other airports where U.S. carriers do not fly that advantages state-owned foreign carriers at the expense of U.S. airlines;
• Ensure that U.S. Open Skies agreements acknowledge that high labor standards for U.S. airline employees are essential to the competitive landscape;
• Eliminate low-interest U.S. Export–Import Bank financing for widebody aircraft that isn’t available to U.S. airlines but subsidizes state-owned foreign airlines and saves them millions in financing costs.

“These state-owned foreign airlines are spending billions to purchase widebody aircraft so they can increase flights to and from the United States and unfairly compete against U.S. airlines in the global marketplace,” said Capt. Moak. “At the same time, the U.S. Export–Import Bank’s below-market financing allows U.S. airlines’ competitors to save millions when they purchase widebody aircraft like those announced this week.”

ALPA strongly maintains that growth in the global airline industry should be driven by fair competition. In providing low-cost financing to foreign airlines, for example, the U.S. Export–Import Bank not only saves the state-owned carriers millions on each aircraft, the financing also enables these airlines to purchase state-of-the-art aircraft that are more fuel efficient and attractive to passengers. As a result, U.S. airlines experience a competitive disadvantage for years if not decades, and the results affect U.S. airline workers throughout the industry.

“The secretary general of the Arab Air Carriers Organization had it half-right in an April 2011 speech to the International Aviation Club in which he compared the U.S. airline industry to dinosaurs that will soon die due to their inability to adapt to their environment,” continued Capt. Moak. “If U.S. airlines are to die, it will be due to U.S. government policy and vision that is stuck in a domestic competitive mindset while we do business in a global economic environment.”

“If U.S. airlines that fly internationally don’t grow because their state-owned foreign competitors benefit from unfair marketplace advantages provided by the U.S. government, the airlines that fly the domestic passengers who connect to the international flights won’t grow either,” said First Officer Marcin Kolodziejczyk, chairman of ALPA’s Mesa Air Group pilot group.

“Skewing global competition against U.S. airlines threatens an economic engine that powers the U.S. gross domestic product and creates good jobs,” concluded Capt. Moak. “U.S. government policies should not disadvantage U.S. airlines while helping our foreign competitors and it is past time for U.S. government leaders to take action to create a fair competitive marketplace for U.S. airlines and their employees.”

Founded in 1931, ALPA is the world’s largest pilot union, representing nearly 50,000 pilots at 32 airlines in the United States and Canada. Visit the ALPA website at www.alpa.org.

El Teniente General Su Alteza Jeque Saif bin Zayed Al Nahyan, Viceprimer Ministro y Ministro del Interior asistió recientemente a la firma de un Memorando de Entendimiento entre el Cuartel General (General Headquarter, GHQ) de la Policía de Abu Dhabi y el Departamento de Policía de Nueva York en los Estados Unidos. El Memorando de Entendimiento tiene como objetivo desarrollar e impulsar la cooperación entre ambas partes en todos los ámbitos del trabajo policial.

La ceremonia contó con la presencia del Mayor General de División Dr. Obeid Al Kutbi, Subcomandante en Jefe de la Policía de Abu Dhabi; el Mayor General Nasser Lakhrebani Al Nuaimi, Secretario General de la Oficina de Su Alteza Viceprimer Ministro y Ministro del Interior; el Mayor General Khalil Dawood Badran, Director General de Finanzas y Servicios; y el Mayor General Ahmed Nasser Al Raisi, Director General de Operaciones Centrales.

El Mayor General Mohammed bin Al Awadhi Al Menhali, Director General de Recursos Humanos de la Policía de Abu Dhabi y el Sr. Raymond Kelly, Jefe de la Policía de Nueva York firmaron el Memorando de Entendimiento en el Cuartel General de la Policía de Abu Dhabi.

La firma del memorando demuestra el entusiasmo por crear una sociedad más segura, con el fin de mejorar la estabilidad y lograr la justicia para todos. Este acuerdo nace de la firme creencia en la necesidad de cooperación entre ambas partes en las áreas del trabajo policial, sobre todo compartir experiencias, participar en cursos de capacitación, aprovechar las técnicas modernas de la policía y el intercambio de información.

También asistieron a la ceremonia de la firma el Coronel Saud Al Saadi, Director de la Secretaría de la Oficina de Su Alteza el Ministro del Interior, un número de oficiales de la Policía de Abu Dhabi; David Cohen, Subcomisionado de la Policía de Nueva York y Brian Burke, Director de la oficina del Comisionado.

Para obtener más información acerca:

del Ministerio del Interior, haga clic AQUÍ

de la Policía de Abu Dhabi, haga clic AQUÍ

Síganos y lea nuestros comunicados en las redes sociales en: YouTube, Facebook y Twitter

*Fuente: ME NewsWire

El texto original en el idioma fuente de este comunicado es la versión oficial autorizada. Las traducciones solo se suministran como adaptación y deben cotejarse con el texto en el idioma fuente, que es la única versión del texto que tendrá un efecto legal.

Le Lieutenant Général S.A. Sheikh Saif bin Zayed Al Nahyan, Vice-Premier Ministre et Ministre de l’Intérieur a assisté récemment à la signature d’un protocole d’accord entre le Siège principal de la Police d’Abu Dhabi et le Département de la Police de New York aux États Unis. Le protocole d’accord vise à développer et à stimuler la coopération entre les deux parties dans tous les aspects du travail de la police.

La cérémonie de signature a eu lieu en présence du Général de Division Dr. Obeid Al Kutbi, Commandant en Chef Adjoint de la Police d’Abu Dhabi, du Général de Division Lakhrebani Al Nuaimi, Secrétaire Général du bureau de S.A. le Vice-Premier Ministre et Ministre de l’Intérieur, du Général de Division Khalil Dawood Badran, directeur général des Finances et des Services et du Général de Division Ahmed Nasser AL Raisi, Directeur Général des Opérations Centrales.

Le Général de Division Mohammed bin Al Awadhi Al Menhali, Directeur Général des Ressources humaines à la Police d’Abu Dhabi et M. Raymond Kelly, Chef de la Police de New York ont signé le protocole d’accord.

La signature du protocole d’accord souligne l’enthousiasme de créer une société plus sûre en vue de renforcer la stabilité et instaurer la justice pour tous. Ce protocole d’accord découle de l’attachement profond à la coopération entre les deux parties dans tous les aspects du travail de la police, notamment l’échange de savoir-faire, la participation aux cours de formation, l’adoption des techniques modernes de police et l’échange des informations.

La cérémonie a eu également lieu en présence du Colonel Saud Al Saadi, Directeur du Secrétariat du Bureau de S.A le Ministre de l’Intérieur, des responsables de la Police d’Abu Dhabi ; de David Cohen, Commissaire Adjoint de la Police de New York et de Brian Burke, Directeur du bureau du Commissaire.

Le texte de la version arabe de ce communiqué est la version officielle faisant autorité. Les traductions sont fournies uniquement à titre d'hébergement, et doivent être renvoyées avec le texte en arabe, qui est la seule version prévue d’avoir un effet juridique.

*Source: ME NewsWire

Pour de plus amples informations sur Le ministère d’Intérieur : Veuillez cliquer ICI

Pour de plus amples informations sur La Police d’Abu Dhabi, Veuillez cliquer ICI

Consulter nos dernières informations sur les médias sociales sur: YouTube, Facebook et Twitter

Oberstleutnant Seine Hoheit der Scheich Saif bin Zayed Al Nahyan, Stellvertretender Ministerpräsident und Innenminister, hat sich vor Kurzem zur Unterzeichnung eines Memorandum of Understanding (einer Absichtserklärung) zwischen dem Abu Dhabi Police GHQ und dem New York Police Department in die USA begeben. Die Absichtserklärung zielt auf die Entwicklung und Förderung der Zusammenarbeit zwischen den beiden Parteien auf allen Gebieten der Polizeiarbeit ab.

An der Zeremonie haben Stabs-Generalleutnant Dr. Obeid Al Kutbi, stellvertretender Oberbefehlshaber der Polizei von Abu Dhabi, Generalleutnant Nasser Lakhrebani Al Nuaimi, Generalsekretär des Büros Seiner Hoheit des stellvertretender Ministerpräsidenten und Innenministers, Generalleutnant Khalil Dawood Badran, Generaldirektor für Finanzen und Dienstleistungen sowie Generalleutnant Ahmed Nasser Al Raisi, Generaldirektor für Zentrale Operationen, teilgenommen.

Generalleutnant Mohammed bin Al Awadhi Al Menhali, Generaldirektor für Personalwesen bei der Polizei Abu Dhabis und Raymond Kelly, Chef der New Yorker Polizei haben im Generalhauptquartier der Abu Dhabi Police die Absichtserklärung unterzeichnet.

Die Unterzeichnung der Absichtserklärung zeigt das starke Interesse für die Schaffung einer sichereren Gesellschaft, mit dem Ziel, die Stabilität zu erhöhen und Gerechtigkeit für alle zu erreichen. Diese Vereinbarung ergibt sich aus der Überzeugung, dass eine Zusammenarbeit zwischen den beiden Parteien in den verschiedenen Bereichen der Polizeiarbeit, insbesondere dem Austausch von Fachwissen, der Teilnahme an Schulungen, dem Einsatz moderner Polizeitechniken und dem Austausch von Informationen notwendig ist.

Ebenfalls bei der feierlichen Unterzeichnung anwesend waren Oberst Saud Al Saadi, Sekretariatsleiter des Büros Seiner Hoheit des Innenministers, eine Reihe von Offizieren der Polizei Abu Dhabis, David Cohen, stellvertretender Kommissar der New Yorker Polizei und Brian Burke, Leiter des Büros des Kommissars.

Weitere Informationen:

VAE-Innenministerium – bitte HIER klicken

Polizei von Abu Dhabi – bitte HIER klicken

Verfolgen Sie auch unsere Beiträge in den sozialen Medien: YouTube, Facebook und Twitter

*Quelle: ME NewsWire

Die Ausgangssprache, in der der Originaltext veröffentlicht wird, ist die offizielle und autorisierte Version. Übersetzungen werden zur besseren Verständigung mitgeliefert. Nur die Sprachversion, die im Original veröffentlicht wurde, ist rechtsgültig. Gleichen Sie deshalb Übersetzungen mit der originalen Sprachversion der Veröffentlichung ab.

O Tenente General Sua Alteza Sheikh Saif bin Zayed Al Nahyan, vice-primeiro-ministro e ministro do interior, participou recentemente da assinatura de um memorando de entendimento entre o quartel general da polícia de Abu Dhabi e o departamento de polícia de Nova York nos Estados Unidos. O memorando de entendimento visa desenvolver e impulsionar a cooperação entre as duas partes em todas as áreas de trabalho policial.

A cerimônia contou com a presença do major-general do estado-maior Dr. Obeid Al Kutbi, comandante-chefe adjunto da polícia de Abu Dhabi; major-general Nasser Lakhrebani Al Nuaimi, secretário-geral do gabinete de Sua Alteza vice-primeiro-ministro e ministro do interior; major-general Khalil Dawood Badran, diretor-geral de finanças e serviços; e major general Ahmed Nasser Al Raisi, diretor geral de operações centrais.

O major-general Mohammed bin Al Awadhi Al Menhali, diretor-geral de recursos humanos da polícia de Abu Dhabi, e o Sr. Raymond Kelly, chefe da polícia de Nova York, assinaram o memorando de entendimento no quartel geral da polícia de Abu Dhabi.

A assinatura do memorando demonstra o entusiasmo para criar uma sociedade mais segura, com vista a aumentar a estabilidade e conseguir justiça para todos. Este acordo deriva da crença firme na necessidade por cooperação entre ambas as partes nas áreas do trabalho policial, principalmente no compartilhamento de conhecimentos, participação em cursos de treinamento, aproveitamento das técnicas modernas de polícia e compartilhamento de informações.

Também participaram da cerimônia de assinatura o coronel Saud Al Saadi, diretor da secretaria do gabinete de Sua Alteza, o ministro do interior; vários oficiais da polícia de Abu Dhabi; David Cohen, comissário adjunto da polícia de Nova York; e Brian Burke, diretor do gabinete do comissário.

Para obter mais informações sobre:

Ministério do Interior, clique AQUI

Polícia de Abu Dhabi, clique AQUI

Siga-nos e confira nossos feeds de Comunicação Social em: YouTube, Facebook e Twitter

*Fonte: ME NewsWire

O texto no idioma original deste anúncio é a versão oficial autorizada. As traduções são fornecidas apenas como uma facilidade e devem se referir ao texto no idioma original, que é a única versão do texto que tem efeito legal.

Aspera, Inc. (http://www.asperasoft.com/), creators of next-generation software technologies that move the world’s large data at maximum speed, today announced that the Australian Government Initiative, the Research Data Storage Infrastructure (http://www.rdsi.uq.edu.au/index.html) (RDSI) Project, working closely with the Australian Government’s National Research Network (NRN) Project (http://www.nrn.edu.au/), is deploying solutions from Aspera to move large data to, from and between nationally-dispersed storage nodes and high-performance computing centers to strengthen Australia's capabilities in data-intensive research collaboration.

“In the research sector, data is everything. Researchers need to have complete and immediate access to the data to be successful and the data sizes are exploding. Aspera software enables scientific researchers to access shared data around the globe while maintaining maximum security and performance”

Funded through the Education Investment Fund under the Super Science (Future Industries) initiative, and led by the University of Queensland, the RDSI project has received A$50 million in federal funding to provide data storage and collaboration infrastructure for Australia’s research community. The project is intended to assist institutions and researchers to more easily and effectively access, use, manage and share large holdings of research data, expanding the scale and scope of problems that Australian researchers may seek to address.

The network consists of eight high-performance data storage locations throughout Australia, with associated Data Transfer Nodes – clusters of high-performance host computers and storage – connected by a fast network optimized for high-performance scientific applications. Aspera Connect Server (http://asperasoft.com/software/transfer-servers/connect-server/) software is being deployed on all hosts in each Data Transfer Node in a high availability configuration to provide ultra high-speed transfers regardless of data size and network distance.

The Aspera Shares (http://asperasoft.com/software/web-applications/aspera-shares/) web application was selected to provide a browser-based, user-friendly overlay for uploading and downloading file content to and from the Nodes and fine-grained control for researchers to manage access to their data, with built-in authentication for the LDAP and single sign-on SAML services, common throughout the research community.

For initial data ingest, researchers simply upload data to the Aspera Connect Server clusters at each Node using the freely downloadable Connect Web Browser Plug-in (http://asperasoft.com/software/transfer-clients/connect-web-browser-plug-in/), which integrates directly with all browser platforms to support high-speed fasp transfers of any file size directly in the browser or from the command line. Once ingested, Aspera Shares provides easy access to shared data with a single web interface to consolidate browsing of shared content across all nodes, enabling fast collaboration between researchers at major universities throughout Australia.

In addition to speed and security, the Aspera technology provides complete control over transfer bandwidth and finish times, and is robust to network outages with automatic retry and resume of even the largest data sets.

During the pilot deployment of the Aspera solution, a research group at a university located in central Queensland, with relatively limited network bandwidth, had an urgent requirement to transfer approximately 1.1TB of data overnight to a government agency in the state capital of Brisbane, where one of the RDSI Nodes is located. The bandwidth management and automatic resume features of the Aspera solution were critical in meeting the deadline, as the transfer could use only 40% of the available bandwidth, and the network link was shut down for several hours during the night for preventative maintenance.

RDSI also selected Aspera Console (http://asperasoft.com/software/automation-management/aspera-console/), the web-based management application, to provide complete visibility over the Aspera transfer environment, including real-time, centralized control over transfers, nodes and users.

“To complement open source data transfer options, we were looking for a commercial solution that is widely available, meets our stringent performance requirements, and is very easy to use. So we deployed Aspera as the data mover for our nodes, and layered the Shares web interface over the top so researchers could more easily access and share their big data. Large file transfer speeds over the fastest parts of the infrastructure are full line speed (10 Gigabits per second) and international transfers with the US have benchmarked at 7-8 Gigabits per second. In addition, the management platform provides us complete visibility into transfer performance,” said Peter Elford, RDSI network program manager.

Another component of the RDSI initiative is to explore the use of cloud storage to support data-intensive research and the researchers who must use, manage and share large and ever-growing data sets. Aspera’s support of cloud-based object storage and commercial Infrastructure as a Service (IaaS) platforms will be explored to determine if and what role cloud services can play in supporting the infrastructure already deployed at the existing storage locations.

“In the research sector, data is everything. Researchers need to have complete and immediate access to the data to be successful and the data sizes are exploding. Aspera software enables scientific researchers to access shared data around the globe while maintaining maximum security and performance,” said Michelle Munson, CEO and co-founder of Aspera. “We are proud and very excited to be a part of the RDSI project and look forward to bringing high-performance transfer software to support its ambitious initiatives for the Australian research community.”

About RDSI

The Research Data Storage Infrastructure (RDSI) Project, an initiative of the Department of Education, is funded from the Education Investment Fund under the Super Science (Future Industries) initiative.

RDSI is a $50m Australian Government funded project, for which the University of Queensland (UQ) is the lead agent.

About Aspera

Aspera is the creator of next-generation transport technologies that move the world’s data at maximum speed regardless of file size, transfer distance and network conditions. Based on its patented, Emmy® award-winning fasp™ protocol, Aspera software fully utilizes existing infrastructures to deliver the fastest, most predictable file-transfer experience. Aspera’s core technology delivers unprecedented control over bandwidth, complete security and uncompromising reliability. Over 2000 organizations across a variety of industries on six continents rely on Aspera software for the business-critical transport of their digital assets. Please visit www.asperasoft.com and follow us on Twitter @asperasoft for more information.

This information was brought to you by Cision http://news.cision.com

Reaching another astronomical milestone, Warner Bros. Pictures’ “Gravity” crossed $500 million at the worldwide box office on Saturday, November 16, 2013. The announcement was made today by Dan Fellman, President of Domestic Distribution, and Veronika Kwan Vandenberg, President of International Distribution, Warner Bros. Pictures.

“This is an outstanding achievement for Alfonso, Sandy and George, and the film’s extraordinary team of innovative artists. We congratulate all of those who brought to life a film that is not only creatively groundbreaking but also beloved by both critics and audiences worldwide.”

Directed by Alfonso Cuarón, “Gravity” has earned an astounding $240.6 million domestically and $274.3 million internationally, for an estimated worldwide total to date of $515 million, and still climbing. From the start, the film has enjoyed record-breaking domestic and international openings, most recently in the UK. It is now the highest-grossing movie ever (worldwide) for its Oscar^®-winning stars, Sandra Bullock and George Clooney.

Box office results for IMAX^® are also very strong, with an estimated $47.1 million domestically, and $24.2 million in 42 overseas markets, for a global total to date of $71.3 million.

In addition, 3D continues to be the format of choice for the vast majority of moviegoers who want to experience the story in the most immersive way possible. The 3D sales represent 81% of the box office domestically and have grown to 80% internationally.

The half-billion mark comes as “Gravity” prepares for two more major openings: in China on November 19, followed by Japan on December 13.

In making the announcement, Fellman said, “This is an outstanding achievement for Alfonso, Sandy and George, and the film’s extraordinary team of innovative artists. We congratulate all of those who brought to life a film that is not only creatively groundbreaking but also beloved by both critics and audiences worldwide.”

Kwan Vandenberg stated, “We are delighted that moviegoers everywhere have embraced 'Gravity' and made it into a global, cinematic event. With anticipation really high for the China and Japan openings, we are expecting even stronger international returns in the coming weeks.”

Academy Award^® winners Sandra Bullock (“The Blind Side”) and George Clooney (“Syriana”) star in “Gravity,” a heart-pounding thriller that pulls you into the infinite and unforgiving realm of deep space. The film was directed by Oscar^® nominee Alfonso Cuarón (“Children of Men”).

Dr. Ryan Stone (Bullock) is a brilliant medical engineer on her first shuttle mission, with veteran astronaut Matt Kowalski (Clooney) in command. But on a seemingly routine mission, disaster strikes. The shuttle is destroyed, leaving Stone and Kowalski completely alone—tethered to nothing but each other and spiraling out into the blackness. The deafening silence tells them they have lost any link to Earth…and any chance for rescue. As fear turns to panic, every gulp of air eats away at what little oxygen is left.

But the only way home may be to go further out into the terrifying expanse of space.

“Gravity” was written by Alfonso Cuarón & Jonás Cuarón, and produced by Alfonso Cuarón and David Heyman (the “Harry Potter” films). Chris deFaria, Nikki Penny and Stephen Jones served as executive producers.

The behind-the-scenes team includes multiple Oscar^®-nominated director of photography Emmanuel Lubezki (“Children of Men,” “The New World”); production designer Andy Nicholson (art director “Alice in Wonderland”); editors Alfonso Cuarón and Mark Sanger (VFX editor “Children of Men”); and costume designer Jany Temime (the “Harry Potter” films). The visual effects were handled by Oscar^®-nominated visual effects supervisor Tim Webber (“The Dark Knight”). The music was composed by Steven Price (“Attack the Block”).

Warner Bros. Pictures Presents an Esperanto Filmoj/Heyday Films Production, an Alfonso Cuarón Film, “Gravity.” The film is being released in 3D and 2D and IMAX^®, and is distributed worldwide by Warner Bros. Pictures, a Warner Bros. Entertainment company. This film has been rated PG-13 for intense perilous sequences, some disturbing images and brief strong language.

gravitymovie.com

)--SC13, the 26th conference in the SC series, welcomes high performance computing researchers, practitioners, and industry leaders this week from around the world. SC is the leading international conference on high performance computing (HPC), networking, storage and analysis, and provides the premier forum for the exchange of information in the global high performance computing community.

“Supercomputing as a discipline is uniquely valuable in our society”

The conference will be held at the Colorado Convention Center, Denver, from Sunday, Nov. 17 to Friday, Nov. 22.

"SC13 marks the 25^th anniversary of the conference series,” said Bill Gropp, the Thomas M. Siebel Chair in Computer Science at the University of Illinois, and the general chair of SC13. “This year we are celebrating the impact that HPC has on each of us every day, and taking a moment to look back at the impact of 25 years of research even as our technical program looks forward to the next quarter century of innovation.”

This year SC includes over 350 of the HPC community’s leading government, academic, and industry organizations showcasing their technologies in more than three acres of exhibit space. The conference features 26 conference rooms dedicated to SC13’s events and programs – from the Exhibitor Forum and tutorials to our many workshops and our new HPC Interconnections program – and two ballrooms of events.

Technical Program

The Technical Program, always the foundation of the conference, provides attendees with insight into the latest research and innovations shaping the future of the HPC industry. The supercomputing community's most established researchers and brightest rising stars contribute the results of their latest efforts to the highly competitive and rigorously reviewed Technical Program of tutorials, papers, panels, workshops and posters.

“Competition for inclusion to the Technical Papers program this year was intense, with 90 of more than 450 submissions accepted, an acceptance rate of less than 20 percent,” observed Satoshi Matsuoka, professor at the Tokyo Institute of Technology and chair of the SC13 Technical Program. “The work here represents the best of the best of HPC.”

Awards

SC is well known for the substantial awards presented by the major computing professional societies: from the IEEE Computer Society Seymour Cray Computer Engineering Award to the ACM Gordon Bell prize, many of these awards are career capstone achievements. This year SC is adding its own award to the mix in celebration of the 25^th anniversary of the conference and in recognition of the tremendous impact that research presented at SC has had on the profession.

“Starting with SC13, the annual Test of Time Award will be presented to a single paper, selected from the conference proceedings between 10 and 25 years ago, that has had true historical impact on the HPC industry,” remarked Dan Reed, awards chair for SC13, Vice-President for Research and Economic Development and Computational Science and Bioinformatics Chair at the University of Iowa.

Impact and New Technologies

SC13 is also continuing its tradition of highlighting how high performance computing advances our quality of life with a new addition to the exhibits this year, the HPC Impact Showcase. The Showcase examines some of the ways HPC shapes our world through testimonials from large and small companies not traditionally associated with SC but who are using HPC to enhance their competitiveness and transform their business practice. There are 16 confirmed participants, from John Deere and Proctor and Gamble to Michael Waltrip Racing and Bank of America, all showcasing innovative and sometimes surprising users of HPC in the products and services we use every day. Another addition to this year’s conference is Emerging Technologies. This peer-reviewed addition to the technical program brings the newest technologies to the exhibit floor, where attendees can interact with the most promising technologies in HPC.

Engaging a Broad Community

Although technologies often take center stage at SC, they are only as effective as the professionals who use them. "SC is as much about people as it is about technology," said Elizabeth Jessup, chair of the new HPC Interconnections program and professor at the University of Colorado Boulder. Supercomputers are complex scientific instruments, and the professionals that design, build, and program them are often highly trained. “We need the talents of a broad range of people as we work to enable HPC users to attempt to solve some of the world’s most pressing problems. This year HPC Interconnections includes initiatives in Broader Engagement, HPC Educators, Mentors & Protégés, a program for international attendees, and programs for students, including the Doctoral Showcase, the Student Job Fair, the Student Cluster Competition, and Student Volunteers. Our goal is simple: to help our newest HPC professionals make meaningful connections for this conference and into the future.”

World-class Speakers

Fifteen speakers from across HPC and the world of science – including a Nobel Laureate and a US National Medal of Science Winner – will share their unique perspectives with the international supercomputing community as part of the invited talks program at SC13. And Australian anthropologist and researcher Genevieve Bell will bring a new perspective to the international supercomputing community as she delivers the keynote talk.

“Supercomputing as a discipline is uniquely valuable in our society,” said Gropp. “As a global leader in the effort to understand how technologies support and transform society, Genevieve’s talk will help our community better understand how we can relate to society more effectively, extending the reach of HPC even further than it goes today.”

World’s Fastest Network

Beginning Saturday, Nov. 16, SC13 will also host the fastest network in the world. Called SCinet, the network is built each year to support the conference. Over 100 engineers representing industry, academia and government institutions have volunteered their time to build the network using more than $20 million in donated equipment and 90 miles of newly installed fiber optic cable lines in the convention center. The network will serve as the primary backbone supporting all 10,000 plus SC13 attendees as they unveil their latest innovations.

“This year SCinet is bringing together multiple 100 Gigabit-per-second (Gbps) circuits in collaboration with leading national and international research networks to provide a total bandwidth of nearly 1 terabit-per-second,” said Trey Breckenridge, Director of High Performance Computing at Mississippi State University and chair of the SCinet. “Networks play a crucial role as science continues to demand more data intensive and distributed computing. SCinet allows the networking community to work closely with scientists and researchers at SC to demonstrate how advanced network technologies can accelerate science.”

Members of the media are invited to visit the conference. Those with valid press credentials can attend for free, but must fill out the online press form at sc13.supercomputing.org.

About SC13

SC13, sponsored by the ACM (Association for Computing Machinery) and the IEEE Computer Society, offers a complete technical program, programs for students and educators in HPC, and an exhibition that together showcase the many ways high performance computing, networking, storage and analysis lead to advances in scientific discovery, research, education and commerce. This premier international conference includes a globally attended technical program, workshops, tutorials, a world class exhibit area, demonstrations and opportunities for hands-on learning.

Dickey’s Barbecue Pit in Eugene will open on Thursday, November 21 with a three-day celebration. The first 50 dine-in customers will receive a gift card for up to $50 to Dickey’s Barbecue Pit.

“I’m excited to bring a different type of restaurant to the Eugene community”

“I’m excited to bring a different type of restaurant to the Eugene community,” said franchise owner Joy Hedge. “This is a very social community and I know people will love the authentic Texas barbecue that we will be serving.”

Friday, customers will enjoy a day full of merchandise giveaways. Then Saturday, radio station New Country 93 will be on site from to noon to 2:00 p.m. and Dickey’s Barbecue will be serving $2 Pulled Pork Barbecue sandwiches. One lucky customer will win a $500 gift card.

Joy Hedge is originally from Oregon and worked in management prior to owning a Dickey’s Barbecue Pit. After learning about the history and growth of the franchise, Hedge and business partners, John Coleman and Nathan Lang, knew they wanted to bring Dickey’s Barbecue Pit to Oregon. Coleman grew up eating Dickey’s Barbecue in Dallas.

The Dickey’s Barbecue Pit in Eugene is located at 1680 Corburg Road next to Side Bar and Dairy Queen and the store number is 541-393-6650. To learn more about this location check out their Facebook page. Click to tweet #DickeysEugene.

About Dickey's Barbecue Restaurants

Dickey’s Barbecue was founded by Travis Dickey with the goal of authentic slow smoked barbecue. More than 72 years later, the Dallas-based family run barbecue franchise still offers a quality selection of signature meats, home style sides, tangy barbecue sauce and free kids meals every Sunday. All meats are slow smoked on site in each restaurant. The fast-casual family-friendly concept has expanded to over 300 locations in 40 states and holds the title of the world’s largest barbecue franchise. This year Technomic named Dickey’s “Fastest-growing restaurant in the country” and they were also named “Best Franchise Deal” by QSR Magazine. For more information, visit Dickey’s or for barbecue franchise opportunities call (866) 340-6188.

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data from two RNAi therapeutic programs for cardiovascular disease, including: ALN-PCSsc, an RNAi therapeutic targeting PCSK9 for the treatment of hypercholesterolemia; and ALN-ANG, an RNAi therapeutic targeting ANGPTL3 for the treatment of genetic forms of mixed hyperlipidemia and severe hypertriglyceridemia. These data were presented at the American Heart Association (AHA) Scientific Sessions held November 16 – 20, 2013 in Dallas, Texas. In a presentation titled “A Subcutaneous Platform for RNAi Therapeutics Targeting Metabolic Diseases: PCSK9 and ANGPTL3,” Alnylam scientists and collaborators presented updated non-human primate (NHP) data showing that subcutaneous administration of ALN-PCSsc led to an up to 95% knockdown of plasma PCSK9 and an up to 67% reduction of low density lipoprotein cholesterol (LDL-C) – in the absence of statin co-administration. In addition, new results were presented for ALN-ANG, showing a greater than 95% reduction of triglycerides and greater than 85% reduction of LDL-C in a rodent model of mixed hyperlipidemia. ALN-PCSsc and ALN-ANG utilize the company’s proprietary GalNAc-siRNA conjugate delivery platform, which is designed to achieve targeted delivery of RNAi therapeutics to hepatocytes through uptake by the asialoglycoprotein receptor, enabling subcutaneous dose administration with a wide therapeutic index. ALN-PCSsc and ALN-ANG are programs in the company’s “Alnylam 5x15” product development and commercialization strategy, where the company aims to advance at least five RNAi therapeutic programs toward genetically validated disease targets into clinical development, including programs in advanced stages, by the end of 2015.

“a major scientific breakthrough that happens once every decade or so”

“Our recent progress with GalNAc-siRNA conjugates enables advancement of subcutaneously administered RNAi therapeutics for the treatment of cardiovascular disease, and our new data presented at the AHA meeting feature our efforts with ALN-PCSsc and ALN-ANG. With ALN-PCSsc, our new study results in non-human primates show an up to 95% knockdown of plasma PCSK9 and an up to 67% reduction of LDL-C – in the absence of statin co-administration, with a very durable knockdown of more than 50 days after the last dose. We believe these results support a highly competitive target product profile, and we look forward to advancing ALN-PCSsc toward clinical trials in 2014 with our partner The Medicines Company,” said Rachel Meyers, Ph.D., Vice President of Research and RNAi Lead Development at Alnylam. “In addition, our scientists presented new data from our discovery program with ALN-ANG. Specifically, a lead GalNAc-siRNA conjugate targeting ANGPTL3 showed a greater than 95% reduction of triglycerides and a greater than 85% reduction of LDL-C in a mouse model of mixed hyperlipidemia. These pre-clinical results phenocopy the human genetics for loss of function in ANGPTL3, and are supportive of our efforts to advance this new RNAi therapeutic program into later stages of pre-clinical development.”

New ALN-PCSsc data presented at AHA are based on studies performed in NHPs. Updated results show that ALN-PCSsc led to an up to 95% knockdown of plasma PCSK9, with mean PCSK9 knockdown at nadir of 87% (p<0.0001 compared with pre-dose values according to ANOVA models) and an up to 67% lowering of LDL-C, with mean LDL-C lowering at nadir of 62% (p<0.0001 compared with pre-dose values). The level of LDL-C reduction was achieved in the absence of statin co-administration. Knockdown of PCSK9 and lowering of LDL-C was rapid and durable, with effects lasting greater than 50 days after the final dose, supportive of the potential for once-monthly dosing and a highly competitive target product profile. In February 2013, Alnylam formed an exclusive global alliance with The Medicines Company for the development and commercialization of the ALN-PCS program, including ALN-PCSsc. Alnylam and The Medicines Company have recently announced selection of their Development Candidate for ALN-PCSsc. Alnylam plans to file an Investigational New Drug (IND) application in 2014 and will lead the program through the completion of Phase I. The Medicines Company is responsible for leading and funding development from Phase II forward and commercializing the ALN-PCS program if successful.

In addition to updating data on the company’s PCSK9 program, Alnylam scientists and collaborators presented new pre-clinical data from the company’s ALN-ANG discovery program. ANGPTL3 is an inhibitor of cellular lipases involved in the metabolism of lipoproteins. Human genetic as well as exome sequencing studies have identified a statistically significant relationship of loss-of-function mutations in ANGPTL3 with decreased levels of triglycerides and LDL-C (N. Engl. J. Med (2010) 363:2220-2227). The new pre-clinical studies were performed in an “ob/ob” mouse model of obesity and mixed hyperlipidemia. A single dose of a GalNAc-siRNA targeting ANGPTL3 was found to lead to robust, dose-dependent knockdown of ANGPTL3 protein, with a single dose ED₅₀ of approximately 1 mg/kg. In a multi-dose experiment, subcutaneous doses of 3.0 mg/kg led to a greater than 95% knockdown of ANGPTL3 protein. This ANGPLT3 protein reduction resulted in a greater than 95% reduction in triglycerides, and a more than 85% reduction in LDL-C. In addition, total cholesterol was reduced by greater than 60%. These new data with ALN-ANG support further advancement of this program for the treatment of genetic forms of mixed hyperlipidemia and severe hypertriglyceridemia, which are associated with increased risk of coronary artery disease and/or recurrent pancreatitis.

“Cardiovascular disease remains the leading cause of mortality worldwide. Elevated LDL-C and triglycerides are two well validated and modifiable risk factors. A substantial number of patients, especially those at high risk for cardiovascular disease, are unable to achieve reduced levels of LDL and triglycerides with current drugs, such as statins or fibrates, and it is clear that new therapeutic options are needed,” said Daniel J. Rader, M.D., professor of Medicine and chief, Division of Translational Medicine and Human Genetics, at the Perelman School of Medicine at the University of Pennsylvania. Dr. Rader also serves on Alnylam’s Scientific Advisory Board. “As a key regulator of LDL receptor levels, liver-expressed PCSK9 is an important and well validated novel target in molecular medicine for the treatment of hypercholesterolemia. Likewise, loss-of-function ANGPTL3 mutations in humans are associated with reduced levels of LDL-C and triglyceride and it is encouraging that an RNAi-based therapeutic targeting ANGPTL3 expression in the liver reproduced these effects in a mouse model. I look forward to continued advancement of novel therapeutics, including RNAi, toward these important disease targets.”

About Hypercholesterolemia

Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood which is known to increase the risk of coronary artery disease, the leading cause of death in the U.S. Some forms of hypercholesterolemia can be treated through dietary restrictions, lifestyle modifications (e.g., exercise and smoking cessation) and medicines such as statins. However, a large proportion of patients with hypercholesterolemia are not achieving target LDL-C goals with statin therapy, including genetic familial hypercholesterolemia patients, acute coronary syndrome patients, high-risk patient populations (e.g., patients with coronary artery disease, diabetics, symptomatic carotid artery disease, etc.) and other patients that are statin intolerant. Severe forms of hypercholesterolemia are estimated to affect more than 500,000 patients worldwide, and as a result, there is a significant need for novel therapeutics to treat patients with hypercholesterolemia whose disease is inadequately managed by existing therapies.

About ALN-PCS

ALN-PCS is a systemically delivered RNAi therapeutic targeting the gene proprotein convertase subtilisin/kexin type 9 (PCSK9), a target validated by human genetics that is involved in the metabolism of low-density lipoprotein cholesterol (LDL-C, or “bad” cholesterol). ALN-PCS therapies are PCSK9 synthesis inhibitors that lower levels of both intracellular and extracellular PCSK9, thereby phenocopying the human genetics observed in loss of function or null human PCSK9 mutations (N. Engl. J. Med. (2006) 354:1264-1272; Am. J. Hum. Genet. (2006) 79: 514-523). PCSK9 synthesis inhibition through an RNAi mechanism has the potential to lower tissue and circulating plasma PCSK9 protein levels resulting in higher LDL receptor levels in the liver, and subsequently lower LDL-C levels in the blood stream. Lower LDL-C is associated with a decreased risk of cardiovascular disease, including myocardial infarction and stroke.

About Mixed Hyperlipidemia and Severe Hypertriglyceridemia

Mixed hyperlipidemia is a genetically inherited condition characterized by very high levels of cholesterol and triglycerides in the blood, both of which are known to increase the risk of coronary artery disease, the leading cause of death in the U.S. It is estimated that as many as 1 out of every 100 individuals have mixed hyperlipidemia and are at increased risk of developing cardiovascular disease. Some forms of mixed hyperlipidemia can be treated through dietary restrictions, lifestyle modifications (e.g., exercise and smoking cessation), and medicines such as statins or fibrates; however, a large portion of mixed hyperlipidemia patients are unable to reach either their LDL-C and/or triglyceride goals with the current standard of care. Patients with severe, inherited forms of hypertriglyceridemia (e.g., familial chylomicronemia syndrome, or “FCS”) are at extremely high risk of developing recurrent pancreatitis. FCS is a rare orphan genetic disease that affects 1 to 2 individuals per million.

About ALN-ANG

ALN-ANG is an RNAi therapeutic targeting the gene angiopoietin-like 3 (ANGPTL3) for the treatment of genetic forms of mixed hyperlipidemia and severe hypertriglyceridemia. ANGPTL3 is a liver-expressed, genetically validated target that acts to inhibit lipoprotein lipase and endothelial lipase, and has been shown to increase plasma triglycerides, as well as low density lipoprotein (LDL) and high density lipoprotein (HDL) cholesterol. Exome sequencing studies have identified a statistically significant relationship of loss-of-function mutations in ANGPTL3 with decreased levels of triglycerides and LDL-C (N. Engl. J. Med (2010) 363:2220-2227). A subcutaneously administered RNAi therapeutic that inhibits ANGPTL3 synthesis and lowers both LDL-C and triglycerides represents a novel approach to the treatment of genetic forms of mixed hyperlipidemia and severe hypertriglyceridemia. ALN-ANG utilizes Alnylam’s proprietary GalNAc conjugate delivery platform enabling subcutaneous dose administration.

About GalNAc Conjugates

GalNAc-siRNA conjugates are a proprietary Alnylam delivery platform and are designed to achieve targeted delivery of RNAi therapeutics to hepatocytes through uptake by the asialoglycoprotein receptor. Research findings demonstrate potent and durable target gene silencing, as well as a wide therapeutic index, with subcutaneously administered GalNAc-siRNAs from multiple “Alnylam 5x15” programs.

About RNA Interference (RNAi)

RNAi (RNA interference) is a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells, and a completely new approach to drug discovery and development. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today which was awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi is a natural process of gene silencing that occurs in organisms ranging from plants to mammals. By harnessing the natural biological process of RNAi occurring in our cells, the creation of a major new class of medicines, known as RNAi therapeutics, is on the horizon. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s RNAi therapeutic platform, target the cause of diseases by potently silencing specific mRNAs, thereby preventing disease-causing proteins from being made. RNAi therapeutics have the potential to treat disease and help patients in a fundamentally new way.

About Alnylam Pharmaceuticals

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers. These include: patisiran (ALN-TTR02), an intravenously delivered RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR) in patients with familial amyloidotic polyneuropathy (FAP); ALN-TTRsc, a subcutaneously delivered RNAi therapeutic targeting TTR for the treatment of ATTR in patients with familial amyloidotic cardiomyopathy (FAC); ALN-AT3, an RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders (RBD); ALN-AS1, an RNAi therapeutic targeting aminolevulinate synthase-1 (ALAS-1) for the treatment of porphyria including acute intermittent porphyria (AIP); ALN-CC5, an RNAi therapeutic targeting complement component C5 for the treatment of complement-mediated diseases; ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of hypercholesterolemia; ALN-TMP, an RNAi therapeutic targeting TMPRSS6 for the treatment of beta-thalassemia and iron-overload disorders; ALN-AAT, an RNAi therapeutic targeting alpha-1-antitrypsin (AAT) for the treatment of AAT deficiency liver disease; and ALN-ANG, an RNAi therapeutic targeting ANGPTL3 for the treatment of genetic forms of mixed hyperlipidemia and severe hypertriglyceridemia, amongst other programs. As part of its “Alnylam 5x15” strategy, the company expects to have five RNAi therapeutic products for genetically defined diseases in clinical development, including programs in advanced stages, on its own or with a partner by the end of 2015. Alnylam has additional partnered programs in clinical or development stages, including ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection and ALN-VSP for the treatment of liver cancers. The company’s leadership position on RNAi therapeutics and intellectual property have enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko Kirin, Cubist, Ascletis, Monsanto, Genzyme, and The Medicines Company. In addition, Alnylam holds an equity position in Regulus Therapeutics Inc., a company focused on discovery, development, and commercialization of microRNA therapeutics. Alnylam has also formed Alnylam Biotherapeutics, a division of the company focused on the development of RNAi technologies for applications in biologics manufacturing, including recombinant proteins and monoclonal antibodies. Alnylam’s VaxiRNA™ platform applies RNAi technology to improve the manufacturing processes for vaccines; GlaxoSmithKline is a collaborator in this effort. Alnylam scientists and collaborators have published their research on RNAi therapeutics in over 100 peer-reviewed papers, including many in the world’s top scientific journals such as Nature, Nature Medicine, Nature Biotechnology, Cell, the New England Journal of Medicine, and The Lancet. Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts. For more information, please visit www.alnylam.com.

About “Alnylam 5x15™”

The “Alnylam 5x15” strategy, launched in January 2011, establishes a path for development and commercialization of novel RNAi therapeutics toward genetically defined targets for the treatment of diseases with high unmet medical need. Products arising from this initiative share several key characteristics including: a genetically defined target and disease; the potential to have a major impact in a high unmet need population; the ability to leverage the existing Alnylam RNAi delivery platform; the opportunity to monitor an early biomarker in Phase I clinical trials for human proof of concept; and the existence of clinically relevant endpoints for the filing of a new drug application (NDA) with a focused patient database and possible accelerated paths for commercialization. By the end of 2015, the company expects to have five such RNAi therapeutic programs in clinical development, including programs in advanced stages, on its own or with a partner. The “Alnylam 5x15” programs include: patisiran (ALN-TTR02), an intravenously delivered RNAi therapeutic targeting transthyretin (TTR) in development for the treatment of TTR-mediated amyloidosis (ATTR) in patients with familial amyloidotic polyneuropathy (FAP); ALN-TTRsc, a subcutaneously delivered RNAi therapeutic targeting TTR in development for the treatment of ATTR in patients with familial amyloidotic cardiomyopathy (FAC); ALN-AT3, an RNAi therapeutic targeting antithrombin (AT) in development for the treatment of hemophilia and rare bleeding disorders (RBD); ALN-AS1, an RNAi therapeutic targeting aminolevulinate synthase-1 (ALAS-1) in development for the treatment of porphyria including acute intermittent porphyria (AIP); ALN-CC5, an RNAi therapeutic targeting complement component C5 in development for the treatment of complement-mediated diseases; ALN-PCS, an RNAi therapeutic targeting PCSK9 in development for the treatment of hypercholesterolemia; ALN-TMP, an RNAi therapeutic targeting TMPRSS6 in development for the treatment of beta-thalassemia and iron-overload disorders; ALN-AAT, an RNAi therapeutic targeting alpha-1-antitrypsin (AAT) in development for the treatment of AAT deficiency liver disease; and ALN-ANG, an RNAi therapeutic targeting ANGPTL3 in development for the treatment of genetic forms of mixed hyperlipidemia and severe hypertriglyceridemia, amongst other programs. Alnylam intends to focus on developing and commercializing certain programs from this product strategy itself in North and South America, Europe, and other parts of the world.

Alnylam Forward-Looking Statements

Various statements in this release concerning Alnylam’s future expectations, plans and prospects, including without limitation, Alnylam’s expectations regarding its “Alnylam 5x15” product strategy, Alnylam’s views with respect to the potential for RNAi therapeutics, including ALN-PCSsc and ALN-ANG, its expectations with respect to further advancing ALN-ANG in development, the filing of an IND application for ALN-PCSsc, its expectations with respect to the timing and success of clinical trials with ALN-PCSsc, and its expectations regarding the potential market opportunity for ALN-PCSsc, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Alnylam’s ability to manage operating expenses, Alnylam’s ability to discover and develop novel drug candidates and delivery approaches, successfully demonstrate the efficacy and safety of its drug candidates, the pre-clinical and clinical results for its product candidates, which may not support further development of product candidates, actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials, obtaining, maintaining and protecting intellectual property, Alnylam’s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties, obtaining regulatory approval for products, competition from others using technology similar to Alnylam’s and others developing products for similar uses, Alnylam’s ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives, Alnylam’s dependence on third parties for development, manufacture, marketing, sales and distribution of products, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the “Risk Factors” filed with Alnylam’s most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings that Alnylam makes with the SEC. In addition, any forward-looking statements represent Alnylam’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation to update any forward-looking statements.